Login to Your Account



Pharma: Clinic Roundup


Thursday, September 27, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it completed enrollment in two Phase III trials testing nintedanib (BIBF 1120) in patients with idiopathic pulmonary fibrosis. The identical studies will enroll a total of 970 patients to receive treatment or placebo over a 52-week period.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription